Melanoma/Skin Cancer News

Linda H. Malkas, PhD, remembers the day a photograph for a newspaper changed her life.

Most patients with cancer diagnosed with myocarditis after receiving immune checkpoint inhibitors showed evidence of liver dysfunction and muscle degradation, results of an observational cohort study in JACC CardioOncology showed.

Most oncology practices deployed immunotherapies as part of their clinical care strategy within 2 years of FDA approval for cancer indications, results of a study in JAMA Oncology showed.

A restrictive opioid prescription protocol of 3 days or less after hospital discharge appeared feasible among a cohort of patients who underwent surgery at a large cancer center, according to study results published in JAMA Oncology.

Melanoma survival rates in children and adolescent patients were around 90% or higher, according to a study.

Cancer drugs that received approval based on increased OS compared with other measures had the lowest median annual cost, according to a research letter published in JAMA Internal Medicine.

Several novel treatment regimens for melanoma/skin cancer emerged during the past year.

The FDA announced several regulatory actions the past few weeks.

Dermatologists should consider ordering a 31-gene expression profile test to determine metastasis risk in patients with newly diagnosed cutaneous malignant melanoma, according to a study.

mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, with Keytruda met the primary endpoint of recurrence-free survival in a phase 2b trial for the adjuvant treatment of stage III/IV melanoma after surgical resection.